Login

FDA Panel Backs COVID-19 Boosters For People 65 And Up, High-Risk Groups

By Kelly Lienhard, Beth Wang / September 17, 2021 at 5:15 PM
FDA’s vaccine advisers on Friday (Sept. 17) voted 18-0 in favor of granting emergency use authorization to a third dose, or booster, of Pfizer’s two-dose COVID-19 vaccine for those 65 and older or at high risk of illness, coming after the advisory committee voted overwhelmingly against approving boosters for people ages 16 and up. FDA initially asked members of its Vaccines and Related Biological Products Advisory Committee to vote on whether the data support approving boosters of Pfizer’s vaccine for...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.